--- title: "Clarivate Sells Its Life-Sciences Arm to Altaris for $600 Million as Shares Jump" description: "The data and analytics group Clarivate has agreed to sell its Life Sciences & Healthcare business to the healthcare investor Altaris for about $600 million, using the proceeds to cut debt and narrow its focus. Its shares rose sharply on the news." category: "Markets" category_url: https://boursel.com/category/markets author: "Sofia Marchetti" published: 2026-07-06T10:37:20.000Z updated: 2026-07-06T10:37:20.000Z canonical: https://boursel.com/article/clarivate-sells-its-life-sciences-arm-to-altaris-for-600-million-as-shares-jump tags: ["clarivate", "m-and-a", "divestiture", "data-analytics", "altaris"] --- # Clarivate Sells Its Life-Sciences Arm to Altaris for $600 Million as Shares Jump The data and analytics group Clarivate has agreed to sell its Life Sciences & Healthcare business to the healthcare investor Altaris for about $600 million, using the proceeds to cut debt and narrow its focus. Its shares rose sharply on the news. Clarivate, a company that sells data and analytics to researchers, universities and law firms, is shedding a business to slim down and pay off debt. It has agreed to sell its Life Sciences & Healthcare segment to the healthcare-focused investment firm Altaris for about $600 million, [Clarivate said](https://www.prnewswire.com/news-releases/clarivate-announces-sale-of-life-sciences--healthcare-segment-for-600-million-302818085.html). Investors welcomed the move: the shares rose sharply, by about 16% in the wake of the announcement, [according to Seeking Alpha](https://seekingalpha.com/news/4611566-clarivate-jumps-16-on-600m-sale-of-life-sciences-segment). ## The terms The $600 million is not all cash on day one. Clarivate will receive $500 million in cash at closing, another $25 million once transition arrangements are complete, and a $75 million "seller note", effectively an IOU from the buyer, [the company said](https://www.prnewswire.com/news-releases/clarivate-announces-sale-of-life-sciences--healthcare-segment-for-600-million-302818085.html). The sale is expected to close by the end of 2026, and Clarivate plans to use the money to reduce its debt and strengthen its balance sheet. ## What Clarivate is keeping Clarivate is best known for research and intellectual-property tools such as Web of Science, a database academics use to track published research, and patent-analytics products used by companies and law firms. After the sale, it will concentrate on two remaining segments, Academia & Government and Intellectual Property, which it says share overlapping customers and technology, [per the company](https://www.prnewswire.com/news-releases/clarivate-announces-sale-of-life-sciences--healthcare-segment-for-600-million-302818085.html). Chief executive Matti Shem Tov framed the deal as part of a "Value Creation Plan to optimize our business model, improve our sales execution, accelerate innovation and rationalize our portfolio," [in the company's statement](https://www.prnewswire.com/news-releases/clarivate-announces-sale-of-life-sciences--healthcare-segment-for-600-million-302818085.html). In plainer terms: sell the piece that fits least well, cut debt, and focus on the parts that do. ## The accounting, and the guidance Divestitures often come with a paper loss, and this one is no exception: Clarivate expects to book a non-cash goodwill impairment of roughly $225 million to $250 million on the sale, [the company said](https://www.prnewswire.com/news-releases/clarivate-announces-sale-of-life-sciences--healthcare-segment-for-600-million-302818085.html). A goodwill impairment is an accounting write-down of value the company had previously assigned to the business; it does not cost cash. Clarivate kept its 2026 forecast intact, guiding to revenue of $2.30 billion to $2.42 billion and adjusted core earnings (EBITDA) of $980 million to $1.04 billion, [according to StockTitan](https://www.stocktitan.net/news/CLVT/clarivate-announces-sale-of-life-sciences-healthcare-segment-for-600-jts6i2ra04gw.html). ## Why the market liked it The share-price jump reflects a common preference among investors for focus and a healthier balance sheet over sprawl. Clarivate had been reviewing its portfolio for months, having flagged a potential sale of the life-sciences unit earlier in the year. Selling it removes a business that fit awkwardly, brings in cash to reduce borrowings, and leaves a simpler company built around its strongest data assets, the kind of tidy-up that markets often reward, even when, as here, it comes with an accounting write-down attached. ## Sources - [Clarivate announces sale of Life Sciences & Healthcare segment for $600 million](https://www.prnewswire.com/news-releases/clarivate-announces-sale-of-life-sciences--healthcare-segment-for-600-million-302818085.html) - [Clarivate jumps 16% on $600M sale of Life Sciences segment](https://seekingalpha.com/news/4611566-clarivate-jumps-16-on-600m-sale-of-life-sciences-segment)